SOURCE: Devgen

March 07, 2007 01:36 ET

Positive outcome of 2006 season of nematicide field trials


Zwijnaarde, March 7, 2007 - Devgen announces positive results of its second year of field trials in which the biological performance of its nematicide compounds and formulations was tested in a variety of crops.

Nematicides are chemical products that control nematodes (roundworms that damage the roots of a large number of crops worldwide, resulting in significant loss in yield and quality). Through its proprietary technology and subsequent field trials across Europe in 2005, Devgen has identified candidate nematicides that demonstrate good efficacy in key crops and have a superior environmental profile versus currently used products.

In order to complete a data package for submission to the regulatory authorities for product approval, a 2 year program of regulatory trials was initiated in March 2006. Devgen focused on efficacy and residue measurement in key nematicide markets (crops such as sugar beet, potato, carrot, tomato, cucumber, melons and peppers) in Northern Europe and Mediterranean countries.

Overall the results were promising and demonstrated:

- reduction of infestation of the crops by nematodes;

- increased yield and/or crop quality at par with the currently used nematicides, which have a less favourable environmental profile;

- residue analysis in line with expectations.

Devgen is thus on track to complete, in a timely fashion, a regulatory data package for submission to the regulatory authorities.

"The more than 120 field trials we conducted over two seasons, have given us substantial experience with our formulations in the field", says Thierry Bogaert, Devgen's CEO. "We remain confident that our products have the favorable profile Devgen is aiming at."

About Devgen

Devgen (Euronext Brussels: DEVG) is an innovator in biotechnology focused on discovering, developing and commercializing:

- a novel generation of biotech products to protect a wide spectrum of crops from damage incurred from pests;

- innovative hybrid rice germplasm and traits focused in Indian farmers needs

- safer and more environmentally friendly agro-chemical products to protect crops from damage inflicted by plant parasitic nematodes;

- novel therapeutic concepts and preclinical drug candidates for treatment of metabolic disease (diabetes, obesity), inflammation and arrhythmia.

Each of these solutions is developed on a platform of in-house designed research, development programs and technologies. Devgen has partnerships with industry leaders in biotechnology and agro chemistry. Incorporated in 1997, Devgen has offices in Ghent (Belgium) and Singapore, with a total work force of over 100 people. For more information on Devgen visit the company's web site

For more information, please contact:

Thierry Bogaert, CEO
+32 9 324 24 24
Devgen press release 07.03.07 English:

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information